| CAS NO: | 1044904-10-0 |
| 包装 | 价格(元) |
| 500μg | 电议 |
| 1mg | 电议 |
| Cas No. | 1044904-10-0 |
| 别名 | (4S)-10-[[二(三氘甲基)氨基]甲基]-4-乙基-4,9-二羟基-1H-吡喃并[3',4':6,7]吲哚嗪并[1,2-B]喹啉-3,14(4H,12H)-二酮 |
| Canonical SMILES | O=C([C@]1(O)CC)OCC2=C1C=C(C(N=C(C=CC(O)=C3CN(C([2H])([2H])[2H])C([2H])([2H])[2H])C3=C4)=C4C5)N5C2=O |
| 分子式 | C23H17D6N3O5 |
| 分子量 | 427.5 |
| 溶解度 | aqueous acid: soluble,Methanol: soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 半岛bd体育手机客户端 描述 | Topotecan-d6 is intended for use as an internal standard for the quantification of topotecan by GC- or LC-MS. Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin .1,2,3 Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay.4 Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells (IC50s = 33 and 280 nM, respectively).1 Formulations containing topotecan have been used in the treatment of small-cell lung cancer. |1. Rothenberg, M.L. Topoisomerase I inhibitors: Review and update. Ann. Oncol. 8(9), 837-855 (1997).|2. Dancey, J., and Eisenhauer, E.A. Current perspectives on camptothecins in cancer treatment. Br. J. Cancer 74(3), 327-338 (1996).|3. Schellens, J.H., Creemers, G.J., Beijnen, J.H., et al. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. Br. J. Cancer 73(10), 1268-1271 (1996).|4. Caceres, G., Zankina, R., Zhu, X., et al. Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors. Anticancer Drugs 14(7), 569-574 (2003). |
m.cnreagent.com